CN107750157B - 含雌四醇的口腔分散片剂 - Google Patents

含雌四醇的口腔分散片剂 Download PDF

Info

Publication number
CN107750157B
CN107750157B CN201680035672.3A CN201680035672A CN107750157B CN 107750157 B CN107750157 B CN 107750157B CN 201680035672 A CN201680035672 A CN 201680035672A CN 107750157 B CN107750157 B CN 107750157B
Authority
CN
China
Prior art keywords
dosage unit
weight
particles
estetrol
aqueous liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680035672.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107750157A (zh
Inventor
S·F·I·哈斯帕特
J·J·普拉图
D·J·M·范登赫费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Publication of CN107750157A publication Critical patent/CN107750157A/zh
Application granted granted Critical
Publication of CN107750157B publication Critical patent/CN107750157B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680035672.3A 2015-06-18 2016-06-20 含雌四醇的口腔分散片剂 Active CN107750157B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15172755 2015-06-18
EP15172755.9 2015-06-18
PCT/EP2016/064181 WO2016203044A1 (en) 2015-06-18 2016-06-20 Orodispersible tablet containing estetrol

Publications (2)

Publication Number Publication Date
CN107750157A CN107750157A (zh) 2018-03-02
CN107750157B true CN107750157B (zh) 2021-07-13

Family

ID=53476702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680035672.3A Active CN107750157B (zh) 2015-06-18 2016-06-20 含雌四醇的口腔分散片剂

Country Status (19)

Country Link
US (1) US10888518B2 (https=)
EP (1) EP3310346B1 (https=)
JP (1) JP6813150B2 (https=)
CN (1) CN107750157B (https=)
CA (1) CA2988362C (https=)
CY (1) CY1124052T1 (https=)
DK (1) DK3310346T3 (https=)
ES (1) ES2877476T3 (https=)
HR (1) HRP20210555T1 (https=)
HU (1) HUE054551T2 (https=)
LT (1) LT3310346T (https=)
MA (1) MA44206B1 (https=)
MD (1) MD3310346T2 (https=)
PL (1) PL3310346T3 (https=)
PT (1) PT3310346T (https=)
RS (1) RS61777B1 (https=)
SI (1) SI3310346T1 (https=)
SM (1) SMT202100350T1 (https=)
WO (1) WO2016203044A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
PT2714712T (pt) 2011-06-01 2016-11-08 Estetra Sprl Processo para a produção de intermediários de estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) * 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) * 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
GB2603868B (en) * 2019-09-27 2023-10-11 Ind Chimica Srl Process for preparing (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-tetrol monohydrate (estetrol monohydrate) and intermediates of said process
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US20230346695A1 (en) 2020-09-29 2023-11-02 Millicent Pharma Limited Orodispersible formulations
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557291A (zh) * 2004-01-14 2004-12-29 杨喜鸿 那格列奈分散片及其制备方法
CN101778635A (zh) * 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
CN104379148A (zh) * 2012-04-19 2015-02-25 列日大学 用于治疗神经障碍的雌激素组分

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
ES2258037T3 (es) 1999-12-02 2006-08-16 Akzo Nobel N.V. Androgenos sustituidos con 14,15-beta-metilen.
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
PT1390040E (pt) 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
EP1390042B1 (en) 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2337129T3 (es) * 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
DE60215224T2 (de) 2002-02-21 2007-08-23 Schering Aktiengesellschaft Pharmazeutische zusammensetzung, enthaltend ein oder mehrere steroide, eine oder mehrere tetrahydrofolatverbindungen und vitamin b12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CN100352445C (zh) 2002-06-11 2007-12-05 潘塔希生物科学股份有限公司 一种皮肤护理组合物及其用途
PT1511496E (pt) 2002-06-11 2007-01-31 Pantarhei Bioscience Bv Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
SI1526856T1 (sl) * 2002-07-12 2008-04-30 Pantarhei Bioscience Bv Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
AU2003264203A1 (en) 2002-08-28 2004-03-19 Robert Casper Estrogen replacement regimen
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
DE60330888D1 (de) 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
AU2003279624A1 (en) 2002-11-08 2004-06-07 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
SI1624878T1 (sl) 2003-05-22 2007-02-28 Pantarhei Bioscience Bv Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine
WO2005030176A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Improved stability of progestogen formulations
PL1670440T3 (pl) 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
WO2005115349A1 (de) 2004-05-28 2005-12-08 Grünenthal GmbH Folsäurehaltiges kontrazeptivum
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
CN101189251B (zh) 2005-05-26 2012-09-12 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
WO2007081206A1 (en) 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
EP1993531B1 (en) 2006-03-02 2015-10-14 Warner Chilcott Company, LLC Extended cycle multiphasic oral contraceptive method
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
SG174785A1 (en) 2006-06-08 2011-10-28 Warner Chilcott Co Llc Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
KR20090029824A (ko) 2006-07-06 2009-03-23 바이엘 쉐링 파마 악티엔게젤샤프트 피임용 및 선천성 기형 위험 예방용 제약 제제
TW200831139A (en) 2006-11-29 2008-08-01 Wyeth Corp Estrogen/SERM and estrogen/progestin bi-layer tablets
WO2008079245A2 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
ATE473746T1 (de) 2007-01-08 2010-07-15 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
EP2155205B1 (en) 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
US20110250274A1 (en) * 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102458386B (zh) 2009-06-23 2016-04-06 拜耳知识产权有限责任公司 用于紧急避孕的药物组合物
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
CN102985070A (zh) 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP2012240917A (ja) * 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
PT2714712T (pt) 2011-06-01 2016-11-08 Estetra Sprl Processo para a produção de intermediários de estetrol
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2013012326A1 (en) 2011-07-19 2013-01-24 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (dhea)
PL2741824T3 (pl) 2011-08-11 2018-03-30 Estetra S.P.R.L. Zastosowanie estetrolu jako środka antykoncepcji awaryjnej
RU2633640C2 (ru) 2011-09-16 2017-10-16 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
RS55231B1 (sr) 2011-10-07 2017-02-28 Estetra Sprl Postupak proizvodnje estetrola
DE202012012822U1 (de) 2011-12-13 2014-02-03 Arstat, Inc. Empfängnisverhütungs-Set zur aufeinanderfolgenden täglichen Anwendung
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) * 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
EP3943079A1 (en) 2013-05-21 2022-01-26 Predictive Therapeutics, LLC Therapeutic and method of use
EP3046928B1 (en) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Process for the preparation of estetrol
JP6447931B2 (ja) 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
HK1251938A1 (zh) 2015-05-18 2019-05-03 敏捷治疗公司 避孕组合物及提高效能和调节副作用的方法
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
RS65196B1 (sr) 2015-06-23 2024-03-29 Laboratorios Leon Farma Sa Kontraceptivno sredstvo na bazi drospirenona za pacijentkinje sa viškom težine
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
SG11202007163WA (en) 2018-02-07 2020-08-28 Estetra Sprl Contraceptive composition with reduced cardiovascular effects

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557291A (zh) * 2004-01-14 2004-12-29 杨喜鸿 那格列奈分散片及其制备方法
CN101778635A (zh) * 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
CN104379148A (zh) * 2012-04-19 2015-02-25 列日大学 用于治疗神经障碍的雌激素组分

Also Published As

Publication number Publication date
HRP20210555T1 (hr) 2021-05-14
EP3310346B1 (en) 2021-03-24
SMT202100350T1 (it) 2021-07-12
CY1124052T1 (el) 2022-05-27
CA2988362C (en) 2022-07-19
SI3310346T1 (sl) 2021-07-30
HK1254649A1 (en) 2019-07-26
RS61777B1 (sr) 2021-06-30
US20180153801A1 (en) 2018-06-07
EP3310346A1 (en) 2018-04-25
LT3310346T (lt) 2021-06-10
CA2988362A1 (en) 2016-12-22
HUE054551T2 (hu) 2021-09-28
MA44206B1 (fr) 2021-04-30
CN107750157A (zh) 2018-03-02
MD3310346T2 (ro) 2021-06-30
JP2018517715A (ja) 2018-07-05
US10888518B2 (en) 2021-01-12
JP6813150B2 (ja) 2021-01-13
ES2877476T3 (es) 2021-11-16
WO2016203044A1 (en) 2016-12-22
PL3310346T3 (pl) 2021-10-25
DK3310346T3 (da) 2021-05-25
PT3310346T (pt) 2021-04-22
MA44206A (fr) 2018-04-25

Similar Documents

Publication Publication Date Title
CN107750157B (zh) 含雌四醇的口腔分散片剂
US12427114B2 (en) Orodispersible dosage unit containing an estetrol component
CN105979935B (zh) 包含雌四醇组分的口崩固体剂量单位
EP3310345B1 (en) Orodispersible tablet containing estetrol
HK1251940A1 (zh) 含雌四醇组分的口腔分散剂量单位
HK1254649B (en) Orodispersible tablet containing estetrol
HK1254486A1 (en) Orodispersible tablet containing estetrol
HK1254486B (en) Orodispersible tablet containing estetrol
HK1254650B (en) Orodispersible dosage unit containing an estetrol component

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191128

Address after: Liege, Belgium

Applicant after: ESTETRA S.A.

Address before: Liege, Belgium

Applicant before: MITHRA PHARMACEUTICALS S.A.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: liege

Patentee after: ESTETRA S.A.

Address before: liege

Patentee before: ESTETRA S.A.